SPT Labtech, which designs and develops automated instrumentation and consumables for life sciences, and BellBrook Labs - a ...

For patients taking medications that don't work as expected or pharmaceutical companies struggling with clinical trial ...

Iambic’s AI-platform includes Enchant, a multimodal transformer model designed to predict both preclinical and clinical endpoints, alongside NeuralPLexer. 1 Enchant recently received Nvidia HGX B200 ...

As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...

The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.

SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life sciences, and BellBrook Labs, a pioneer in high-throughput screening (HTS) assay tools, ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda ...

Digital twins revolutionize drug discovery by integrating AI and biological data, enhancing prediction, trial design, and decision-making in precision medicine.

The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug ...

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...

Iambic Therapeutics, a San Diego–based start-up that harnesses physics and artificial intelligence for drug discovery, is ...